Israeli biotech Neurim (featured Nov 20) has signed marketing agreements for its new Rx PedPRM treatment for sleep disorders in children with autism spectrum disorders and neurogenetic diseases. Kuhnil will market Rx PedPRM in Korea; Aspen in Australia and New Zealand.

http://www.neurim.com/news/2016-12-06/neurim-pharmaceuticals-paediatric-prolonged-release-melatonin-pedprm-to-be-marketed-by-kuhnil-pharmaceutical-in-south-korea/